Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer with poor clinical prognosis and limited targeted treatment strategies. Kinase inhibitor screening of a panel of 20 TNBC cell lines uncovered three critical TNBC subgroups: 1) sensitive to only MEK inhibitors; 2) sensitive to only Akt inhibitors; 3) resistant to both MEK/Akt inhibitors. Using genomic, transcriptomic and proteomic datasets of these TNBC cell lines we unravelled molecular features associated with the MEK and Akt drug resistance. MEK inhibitor-resistant TNBC cell lines were discriminated from Akt inhibitor-resistant lines by the presence of PIK3CA/PIK3R1/PTEN mutations, high p-Akt and low p-MEK levels, yet these features could not distinguish double-resistant cells. Gene set enrichment analyses of transcriptomic and proteomic data of the MEK and Akt inhibitor response groups revealed a set of cell cycle-related genes associated with the double-resistant phenotype; these genes were overexpressed in a subset of breast cancer patients. CDK inhibitors targeting the cell cycle programme could overcome the Akt and MEK inhibitor double-resistance. In conclusion, we uncovered molecular features and alternative treatment strategies for TNBC that are double-resistant to Akt and MEK inhibitors.

Additional Metadata
Persistent URL dx.doi.org/10.1038/s41598-019-49809-3, hdl.handle.net/1765/119797
Journal Scientific Reports
Citation
van der Noord, V.E. (Vera E.), McLaughlin, R.P. (Ronan P.), Smid, M, Foekens, J.A, Martens, J.W.M, Zhang, Y. (Yinghui), & Van de Water, B. (2019). An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer. Scientific Reports, 9(1). doi:10.1038/s41598-019-49809-3